Goldman Sachs Initiates Acorda Therapeutics With Neutral

Analysts at Goldman Sachs initiated coverage on shares of Acorda Therapeutics ACOR with a Neutral rating. The target price for Acorda Therapeutics is set to $40. Acorda Therapeutics shares have surged 15.26% over the past 52 weeks, while the S&P 500 index has gained 14.78% in the same period. Acorda Therapeutics' shares fell 1.19% to close at $36.40 yesterday.